Navigation Links
t2cure First Company to Have Quality of Cellular Therapeutic Certified by EMA
Date:5/25/2010

FRANKFURT, May 25, 2010 /PRNewswire/ -- t2cure GmbH, a biopharmaceutical company developing and marketing stem cell-based regenerative therapies, announced today that the quality of its lead product t2c001 has been certified by the European Medicines Agency (EMA).

t2c001 is the first product ever to obtain a certificate under the EMA regulations for Advanced Therapy Medicinal Products (ATMPs). It is a somatic cell therapy product derived from autologous bone marrow, that is currently developed for the treatment of cardiovascular diseases. ATMPs are advanced biotechnology products based on cell therapy, gene therapy, or tissue engineering.

"We are absolutely excited that our lead product has been confirmed to meet the rigorous quality requirements set by the EMA, the regulatory body that will decide on a future European market approval for our product", commented Dr Petra Rueck, CEO of t2cure. "Together with upcoming 5-year efficacy and safety data from our Phase II trial, the EMA Certification shows that we are on the right track to bring this groundbreaking therapy closer to the market, and to patients."

Rueck continued: "This achievement also proves that the regulations set out by the EMA for advanced therapy products and the expertise brought together by the EMA's Committee for Advanced Therapies effectively assist small and medium-sized companies in developing advanced therapy products. These products offer novel treatment opportunities for patients who suffer from diseases, including orphan diseases, for which there are limited or no treatment options."

ATMPs and European Regulation on ATMPs

Advanced therapy medicinal products (ATMPs) based on cell therapy, gene therapy, or tissue engineering are at the forefront of biotechnology and medical innovation. Because of their novelty and complexity, evaluating the quality, safety, and efficacy of ATMPs often requires the development of alternative approaches that go beyond what is needed for conventional medicines. For example, testing the stability of a cell therapy product containing living cells derived from the patient's body requires a fundamentally different methodology from testing traditional pharmaceuticals.

In response to these challenges the European Regulation 1394/2007 provided a consolidated framework for this innovative class of products, including a procedure allowing small and medium-sized companies to voluntarily apply for the Certification of the pharmaceutical quality and the pre-clinical data of an advanced therapy product.

While the Certification procedure is independent from a Marketing Authorization Application (MAA), it follows the scientific and technical requirements necessary to facilitate a future MAA. The Certification confirms that the data submitted for an ATMP meet the same scientific and technical standards that apply to current regulation of other pharmaceutical and biotechnology products, including among others requirements regarding GMP, GCP, and stability.

A Certificate issued by the European Medicines Agency (EMA) is based on the evaluation by the members of its Committee for Advanced Therapies (CAT). The CAT is a multidisciplinary committee bringing together several of the best available European experts to assess the quality, safety, and efficacy of advanced therapy products.

For more information on the European ATMP regulation, including on CAT members and on the Certification procedure, see http://www.ema.europa.eu/htms/human/advanced_therapies/intro

About t2cure GmbH

t2cure GmbH is a biopharmaceutical company engaged in the field of stem cell-based regenerative medicine. It develops and markets autologous bone marrow-derived progenitor cells as regenerative therapeutics for cardiovascular diseases including ischemic heart disease (acute myocardial infarction and chronic ischemic heart disease), non-ischemic heart failure and peripheral arterial disease. The most advanced project (t2c001-AMI) has successfully passed Phase II of clinical development and is commercially available to treat patients in Germany.

t2cure is privately financed by Entrepreneurs Fund and Kreditanstalt fuer Wiederaufbau.

    For more information on the Company, visit our website
http://www.t2cure.com

    Company contact:

    Dr. Petra Rueck
    t2cure GmbH
    Bettinastrasse 35-37
    D-60325 Frankfurt am Main
    Tel: +49-69-75-61-46-87-0
    Fax: +49-69-75-61-46-87-9
    Email: info@t2cure.com
    http://www.t2cure.com

    Media contact:

    Frank Butschbacher
    Investor Relations & Communications
    http://www.butschbacher.net
    +43-650-7844940
    office@butschbacher.net



'/>"/>
SOURCE t2cure GmbH
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Stem Cell Company t2cure Appoints Dr Rueck Head of Clinical Operations
2. t2cure Acquires Patent Family on In Vitro Potency Testing of Stem Cells for Cardiovascular Application
3. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
4. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
5. Kewaunee Scientific Announces First Quarter Results and Quarterly Dividend
6. Genmab Announces 2007 First Half Year Results
7. Pharsight Achieves First License Sale for Public-Source Database
8. Novare Announces First Ever Single Port Laparoscopic Kidney Removal (Nephrectomy) Using RealHand(TM) HD Instruments
9. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
10. China Medical Technologies Reports First Quarter Financial Results
11. Pressure BioSciences, Inc. Issued First Patent in Canada
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 27, 2016  Sequenom, Inc. (NASDAQ: SQNM ... lives through the development of innovative products and services, ... the United States denied its petition to ... of Sequenom,s U.S. Patent No. 6,258,540 (",540 Patent") are ... by the Supreme Court,s Mayo Collaborative Services v. Prometheus ...
(Date:6/27/2016)... , ... June 27, 2016 , ... ... bring innovative medical technologies, services and solutions to the healthcare market. The company's ... of various distribution, manufacturing, sales and marketing strategies that are necessary to help ...
(Date:6/27/2016)... , June 27, 2016   Ginkgo Bioworks ... to industrial engineering, was today awarded as one ... selection of the world,s most innovative companies. Ginkgo ... scale for the real world in the nutrition, ... engineers work directly with customers including Fortune 500 ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial ... Cary 5000 and the 6000i models are higher end machines that use the more ... the spectrophotometer’s light beam from the bottom of the cuvette holder. , FireflySci ...
Breaking Biology Technology:
(Date:4/28/2016)... Sweden , April 28, 2016 First ... M (139.9), up 966% compared with the first quarter of 2015 ... profit totaled SEK 589.1 M (loss: 18.8) and the operating margin ... 7.12 (loss: 0.32) Cash flow from operations was SEK ... The 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. ...
(Date:4/19/2016)... -- The new GEZE SecuLogic access control ... system solution for all door components. It can be ... interface with integration authorization management system, and thus fulfills ... dimensions of the access control and the optimum integration ... considerable freedom of design with regard to the doors. ...
(Date:4/14/2016)... BioCatch ™, the global ... the appointment of Eyal Goldwerger as CEO. ... Goldwerger,s leadership appointment comes at a time of significant ... of its platform at several of the world,s largest ... unique cognitive and physiological factors, is a winner of ...
Breaking Biology News(10 mins):